SunWay Biotech Co., Ltd. (1271.TWO) Fundamentals
As of May 25, 2026
TL;DR — SunWay Biotech Co., Ltd. (1271.TWO) fundamentals as of May 25, 2026
SunWay Biotech Co., Ltd. (1271.TWO) trades at a trailing P/E of 35.7x and a P/B of 1.12x. Return on equity is 311.0%, return on invested capital is 237.0%, and the company carries a debt-to-equity ratio of 0.08. The current ratio sits at 1.93, free cash flow yield is 302.0%, and the dividend yield is 220.0%. MIXED — passes most quality screens but at least one flag warrants a closer look.
For intrinsic value (DCF, owner earnings, Graham number) and the full 5-pillar score, see the 1271.TWO overview page.
Full Fundamentals Table
Every key indicator we track for 1271.TWO fundamentals, grouped by category. Industry median is shown where a sector classification is available.
| Metric | 1271.TWO | Consumer Defensive median | What it measures |
|---|---|---|---|
| Revenue (TTM) | View full statement | - | Trailing twelve-month total revenue |
| Net Income (TTM) | View full statement | - | Bottom-line profit after taxes and interest |
| Free Cash Flow (TTM) | View full statement | - | Cash from operations minus CapEx |
| EPS (TTM) | N/A | - | Earnings per diluted share |
| ROE | 311.0% | 19% | Return on Equity — net income / shareholder equity |
| ROA | 268.0% | - | Return on Assets — net income / total assets |
| ROIC | 237.0% | - | Return on Invested Capital — NOPAT / (debt + equity) |
| P/E (Trailing) | 35.7x | 19x | Price / earnings — how many years of profit to recoup price |
| P/B | 1.12x | 4.5x | Price / book value — premium over net assets |
| P/S | 3.65x | - | Price / sales — useful when earnings are noisy |
| EV/EBITDA | 27.1x | - | Enterprise value / EBITDA — capital-structure neutral |
| Debt / Equity | 0.08 | 0.80 | Leverage — lower = less reliance on debt |
| Current Ratio | 1.93 | - | Current assets / current liabilities — short-term liquidity |
| Dividend Yield | 220.0% | - | Annual dividend / current price |
5-Year Trend
Indexed revenue growth path for 1271.TWO over the past five fiscal years (base = 100). Used as a quick sanity check on whether the top line is compounding or stalling.
Trend indexed from 1-year revenue growth rate. Full statement available in the analyst tier.
Industry Comparison
Across Consumer Defensive, the median company prints P/E around 19x, P/B near 4.5x, ROE close to 19%, and a debt-to-equity ratio of 0.8. 1271.TWO's reading on each metric is in the ratio table above — anything materially above the median valuation multiple deserves a thesis to justify the premium, anything materially below the median return-on-capital flags an operational gap.
Compare 1271.TWO side-by-side with sector peers in the Consumer Defensive stock list.
Quality Triple Check
Piotroski F-Score
Nine-point checklist for accounting quality and operational efficiency
4/9
FLAG
Beneish M-Score
Earnings-manipulation detector — below -2.22 is healthy
-2.34
PASS
Altman Z-Score
Bankruptcy-risk model — above 2.99 is "safe zone"
4.75
PASS
Verdict: MIXED — passes most quality screens but at least one flag warrants a closer look.
Next steps
- View the full 1271.TWO overview for intrinsic value (DCF), margin of safety, and the 5-pillar VM Score.
- Check the 1271.TWO beta page for volatility vs the S&P 500.
- Look at the 1271.TWO P/E ratio page for the 10-year valuation context.
- Dig into the 1271.TWO debt-to-equity page for leverage trends.
- Run your own model in the DCF calculator.
Frequently asked about 1271.TWO fundamentals
What are the key fundamentals for SunWay Biotech Co., Ltd. (1271.TWO)?↓
The core 1271.TWO fundamentals are P/E 35.7, ROE 311.0%, ROIC 237.0%, debt/equity 0.08, and dividend yield 220.0%. The complete ratio table on this page covers revenue, net income, FCF, EPS, ROA, P/B, P/S, EV/EBITDA, and current ratio.
How does 1271.TWO compare to its Consumer Defensive peers?↓
The Consumer Defensive sector median P/E is roughly 19x, ROE 19%, and D/E 0.8. 1271.TWO prints P/E 35.7, ROE 311.0%, and D/E 0.08. Use the Industry Comparison row in the ratio table for the full diff.
Does 1271.TWO pass the Quality Triple Check?↓
1271.TWO passes 2 of 3 quality screens (Piotroski F-Score, Beneish M-Score, Altman Z-Score). Detailed verdict above.
How is "fundamentals" different from intrinsic value?↓
Fundamentals describe what the business looks like today: profit, cash flow, leverage, returns on capital. Intrinsic value uses those fundamentals as inputs to a DCF (or similar model) and discounts the future cash flows back to today. Use both — fundamentals tell you whether a business is healthy, intrinsic value tells you whether the price is fair.
How often does ValueMarkers update 1271.TWO fundamentals?↓
Cached financial statements refresh every 12 hours. The ratio table on this page is rebuilt every 6 hours via Next.js ISR, and the underlying FMP data refreshes on each new earnings release.